Clinical trial participation is associated with improved outcome in women with ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 1, 2009, Pages 124-128

  Robinson, William R ^a,b   Ritter, Joyce ^a   Rogers, April S ^a   Tedjarati, Sean ^a   Lieberenz, Christy ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Harrington Cancer Center   (United States)

Author keywords

Clinical trials; Ethics; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENTIALITY; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; HISTOPATHOLOGY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RURAL AREA; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME; URBAN AREA; MORTALITY; OVARY TUMOR; REGISTER; SURVIVAL;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; REGISTRIES; SURVIVAL ANALYSIS;

EID: 65649104455     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGJ.0b013e31819a1ce8     Document Type: Article

References (23)

1. Bookman MA. First-line randomized trials: revisiting the Ptolemaic universe. Int J Gynecol Oncol. 2008;18(Suppl 1):47-52.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6.
3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.
5. Markman JR Markman M. Running an ethical clinical trial 60 years after the Nuremberg Code. Lancet Oncol. 2007;8(12):1139-1146.
6. Society of Gynecologic Oncologists. Clinical Practice Guidelines. Available at: www.sgo.org. Accessed June 2008.
7. American Society of Clinical Oncology Annual Meeting Press ReleaseVJune, 2007. ASCO News & Forum Column Highlights Cooperative Group-Sponsored Clinical Trials, Encourages Patient Accrual to These Vital Research Initiatives. Available at: www.asco.org.
8. National Comprehensive Cancer Network Guidelines. NCCN Clinical Practice Guidelines in Oncology. Available at: www.nccn.org. Accessed January 2008.
9. Robinson WR, Davis N, Rogers AS. Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2008;18:891-895.
10. Davis S, Wright PW, Schulman SF, et al. Participants in prospective, randomized clinical trials for resected nonYsmall cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer. 1985;56:1710-1718.
11. Bertelsen K, Andersen JE. Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusion. Int J Gynecol Oncol. 1994;4(3):180-187.
12. Dowling AJ, Czaykowski PM, KrahnMD, et al. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol. 2000;163:1481-1485.
13. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 2001;91:2246-2257.
14. Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet. 2004;363:263-270.
15. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
16. Parsons HM. What happened at Hawthorne? Science. 1974;183:93.
17. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systemic review of rigorous evaluations. Lancet. 1993;342(8883):1317-1322.
18. Du Bois A, Rochon J, Lamparter C, et al. Pattern of care and impact of participation in clinical trials on outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15:183-191.
19. Harter P, du Bois A, Schade-Brittinger C, et al. Non-enrollment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol. 2005;16:1801-1805.
20. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Fifth Revision. Bulletin World Health Organ. 2008;86:650-651.
21. Angell M. Ethical imperialism? Ethics in international collaborative clinical research. N Engl J Med. 1988;319:1081-1083.
22. Vastag B. Helsinki discord? A controversial declaration. JAMA. 2000;284:2983-2985.
23. Luck MB, McIntire M, Blades N, Robinson W. Characteristics of women with gynecologic cancer who enter clinical trials. J Reprod Med. 2005;50:481-485.